- Home
- PULM vs NCEL Comparison
PULM vs NCEL Comparison
Compare PULM & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | NCEL |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 10.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PULM | NCEL |
|---|---|---|
| Price | $1.34 | $2.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 49.8K | 19.7K |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,910,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.16 | $1.83 |
| 52 Week High | $9.37 | $4.70 |
Technical Indicators
Market Signals| Indicator | PULM | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 66.73 |
| Support Level | $1.18 | $2.44 |
| Resistance Level | $4.97 | $3.16 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 61.29 | 97.87 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.